I

Integrated Biosciences

AI-driven synthetic biology therapeutics discovery

Executive Assistant

Full-TimeUpdated on 10/23/2026
$90k - $130k+ Equity + Performance bonus
Junior
Bachelor's, Master's
Redwood City, CA, USA
In PersonIn-person role at Redwood LIFE in Redwood City, California.
Administrative & Executive AssistanceExecutive Support
H1B Sponsorship Available

About the job

Requirements
  • A bachelor's or master's degree in a science or business-related field.
  • At least 2 years of experience supporting a C-level executive, founder, or partner in a fast-moving environment such as a startup, biotech, venture capital, or banking.
  • A track record of discretion with sensitive information that references can verify.
  • Strong organization and prioritization, with calm execution under pressure and changing priorities.
  • Direct, concise communication.
  • Sound judgment about what to handle, what to escalate, and when.
  • Fluency with Google Workspace, Slack, and AI tools such as ChatGPT or Claude.
Responsibilities
  • Coordinate the CEO's calendar, prioritize requests, protect focus time, and decline requests gracefully.
  • Triage the CEO's inbox and communications, draft responses, and surface only items requiring the CEO's attention.
  • Prepare the CEO for meetings with agendas, briefs, and materials, and track follow-ups to completion.
  • Coordinate travel, expenses, and scheduling with investors, board members, advisors, and partners.
  • Run the day-to-day administrative operations of the CEO's office and anticipate and resolve problems before they reach the CEO.
  • Handle confidential information with discretion.
Desired Qualifications
  • Experience supporting a CEO or founder at a venture-backed startup or life sciences company.
  • Experience coordinating board meetings, legal and human resources paperwork, and investor logistics.
  • Event planning experience for offsites, team events, or scientific advisory board meetings.
  • Interest in biotech, especially therapeutics and drug discovery.

About the company

I

Integrated Biosciences

View

Integrated Biosciences develops therapies for age-related diseases using a platform that blends synthetic biology, AI-driven small-molecule drug discovery, optogenetics, chemistry, and computation. The platform helps scientists understand complex cellular stress biology and identify compounds that modulate stress responses linked to neurodegeneration, cancer, and diabetes. Drugs are discovered and developed through research and development efforts, with the goal of bringing new therapeutics to patients. Unlike traditional pharma approaches that rely on a single method, Integrated Biosciences combines biology engineering, machine learning, and precision chemistry to accelerate the discovery and optimization of drug candidates.

Company Size

11-50

Company Stage

Late Stage VC

Total Funding

$85.6M

Headquarters

Redwood City, California

Founded

2022

Get referred to Integrated Biosciences

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • August 2026 fundraising reports $68.4 million, extending runway after the 2024 $17.2 million seed.
  • Tony Wu joined the Scientific Advisory Board in February 2026, adding frontier-model expertise.
  • The company touts sixfold senolytic hit-rate gains and multi-year LVMH research support.

What critics are saying

  • Integrated Biosciences still has no disclosed clinical candidate or human trial by September 2026.
  • The platform depends on unproven AI biology translation; failures before 2027 erase valuation.
  • LVMH and seed financing do not guarantee drug approvals, and commercialization remains years away.

What makes Integrated Biosciences unique

  • Jim Collins, David MacMillan, and Daniel Anderson anchor a rare aging-drug discovery bench.
  • Optogenetics plus AI enables precise transcriptome control, unlike standard virtual screening.
  • LVMH Recherche partnership broadens the platform into beauty, not only therapeutics.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • 401(k) Company Match
  • Company Equity

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

14%

2 year growth

6%
Medium
Aug 13th, 2026
$771.8M Across 5 Fresh SEC Form D Raises This Week

Five new SEC Form D filings hit EDGAR this week, together raising $771.8M. Here’s the roundup, scored for B2B sales relevance by Funding…

Investors Hangout
May 19th, 2026
Integrated Biosciences raises $17M to develop age-related disease treatments with AI

Integrated Biosciences has secured $17.2 million in seed financing led by Sutter Hill Ventures to develop therapeutics targeting age-related diseases. The company combines synthetic biology and artificial intelligence to enhance drug discovery, employing techniques including optogenetics for precise cellular data control. The funding will accelerate development of the company's drug pipeline, enhance its platform and support commercialisation efforts. Integrated Biosciences benefits from advisors with expertise in medical engineering, systems biology and drug development, providing insight into translational medicine. The company's approach uses machine learning alongside synthetic biology to innovate the drug discovery process for age-related conditions.

Business Wire
Feb 19th, 2026
xAI co-founder Tony Wu joins Integrated Biosciences' scientific advisory board

Integrated Biosciences, a biotechnology company using optogenetics, chemistry and AI to discover therapeutics for age-related diseases, has appointed Tony Wu, co-founder of xAI, to its Scientific Advisory Board. Wu played a key role in building Grok, xAI's reasoning and agentic AI model, and scaling the Colossus supercomputer cluster. His expertise in large-scale model training and AI applications to scientific discovery will support Integrated Biosciences' platform, which has demonstrated sixfold improvements in hit rates for senolytic compounds and breakthroughs in virtual staining and biological age inference from microscopy. The appointment strengthens the company's advisory board, which includes experts in ageing biology, drug discovery and a Nobel Prize winner in chemistry. Integrated Biosciences is based in Redwood City, California.

Associated Press
Jan 27th, 2026
Integrated Biosciences names Daniel Anderson chief scientific officer to advance age-related disease pipeline

Integrated Biosciences has appointed Daniel J. Anderson as chief scientific officer. Anderson joins from Eikon Therapeutics, where he served as CSO and managed a team of 130 scientists leading discovery and translational research efforts. In his new role, Anderson will oversee scientific strategy and pipeline development at Integrated Biosciences, which combines synthetic biology, chemistry and AI to discover small-molecule therapeutics for age-related diseases. He previously held positions at Recursion Pharmaceuticals, Cleave Biosciences and Genentech, advancing 10 programmes into clinical trials. Max Wilson, co-founder of Integrated Biosciences, has moved to chief technology officer, where he will focus on advancing the company's technology platform, including AI-enabled discovery systems and high-throughput biological screening.

Business Wire
Oct 8th, 2024
Integrated Biosciences Raises $17 Million to Accelerate Development of Drugs Targeting Age-Related Diseases

Integrated Biosciences, a biotechnology company pioneering the use of synthetic biology and machine learning to develop next-generation therapeutics f